AIMS/HYPOTHESIS: IRS-1 serine phosphorylation is often elevated in insulin resistance models, but confirmation in vivo in humans is lacking. We therefore analysed IRS-1 phosphorylation in human muscle in vivo. METHODS: We used HPLC-electrospray ionisation (ESI)-MS/MS to quantify IRS-1 phosphorylation basally and after insulin infusion in vastus lateralis muscle from lean healthy, obese non-diabetic and type 2 diabetic volunteers. RESULTS: Basal Ser323 phosphorylation was increased in type 2 diabetic patients (2.1 ± 0.43, p ≤ 0.05, fold change vs lean controls). Thr495 phosphorylation was decreased in type 2 diabetic patients (p ≤ 0.05). Insulin increased IRS-1 phosphorylation at Ser527 (1.4 ± 0.17, p ≤ 0.01, fold change, 60 min after insulin infusion vs basal) and Ser531 (1.3 ± 0.16, p ≤ 0.01, fold change, 60 min after insulin infusion vs basal) in the lean controls and suppressed phosphorylation at Ser348 (0.56 ± 0.11, p ≤ 0.01, fold change, 240 min after insulin infusion vs basal), Thr446 (0.64 ± 0.16, p ≤ 0.05, fold change, 60 min after insulin infusion vs basal), Ser1100 (0.77 ± 0.22, p ≤ 0.05, fold change, 240 min after insulin infusion vs basal) and Ser1142 (1.3 ± 0.2, p ≤ 0.05, fold change, 60 min after insulin infusion vs basal). CONCLUSIONS/ INTERPRETATION: We conclude that, unlike some aspects of insulin signalling, the ability of insulin to increase or suppress certain IRS-1 phosphorylation sites is intact in insulin resistance. However, some IRS-1 phosphorylation sites do not respond to insulin, whereas other Ser/Thr phosphorylation sites are either increased or decreased in insulin resistance.
AIMS/HYPOTHESIS: IRS-1serine phosphorylation is often elevated in insulin resistance models, but confirmation in vivo in humans is lacking. We therefore analysed IRS-1 phosphorylation in human muscle in vivo. METHODS: We used HPLC-electrospray ionisation (ESI)-MS/MS to quantify IRS-1 phosphorylation basally and after insulin infusion in vastus lateralis muscle from lean healthy, obese non-diabetic and type 2 diabetic volunteers. RESULTS: Basal Ser323 phosphorylation was increased in type 2 diabeticpatients (2.1 ± 0.43, p ≤ 0.05, fold change vs lean controls). Thr495 phosphorylation was decreased in type 2 diabeticpatients (p ≤ 0.05). Insulin increased IRS-1 phosphorylation at Ser527 (1.4 ± 0.17, p ≤ 0.01, fold change, 60 min after insulin infusion vs basal) and Ser531 (1.3 ± 0.16, p ≤ 0.01, fold change, 60 min after insulin infusion vs basal) in the lean controls and suppressed phosphorylation at Ser348 (0.56 ± 0.11, p ≤ 0.01, fold change, 240 min after insulin infusion vs basal), Thr446 (0.64 ± 0.16, p ≤ 0.05, fold change, 60 min after insulin infusion vs basal), Ser1100 (0.77 ± 0.22, p ≤ 0.05, fold change, 240 min after insulin infusion vs basal) and Ser1142 (1.3 ± 0.2, p ≤ 0.05, fold change, 60 min after insulin infusion vs basal). CONCLUSIONS/ INTERPRETATION: We conclude that, unlike some aspects of insulin signalling, the ability of insulin to increase or suppress certain IRS-1 phosphorylation sites is intact in insulin resistance. However, some IRS-1 phosphorylation sites do not respond to insulin, whereas other Ser/Thr phosphorylation sites are either increased or decreased in insulin resistance.
Authors: Y F Liu; K Paz; A Herschkovitz; A Alt; T Tennenbaum; S R Sampson; M Ohba; T Kuroki; D LeRoith; Y Zick Journal: J Biol Chem Date: 2001-01-29 Impact factor: 5.157
Authors: M Pende; S C Kozma; M Jaquet; V Oorschot; R Burcelin; Y Le Marchand-Brustel; J Klumperman; B Thorens; G Thomas Journal: Nature Date: 2000 Dec 21-28 Impact factor: 49.962
Authors: K Cusi; K Maezono; A Osman; M Pendergrass; M E Patti; T Pratipanawatr; R A DeFronzo; C R Kahn; L J Mandarino Journal: J Clin Invest Date: 2000-02 Impact factor: 14.808
Authors: Clinton Mielke; Natalie Lefort; Carrie G McLean; Jeanine M Cordova; Paul R Langlais; Andrew J Bordner; Jerez A Te; S Banu Ozkan; Wayne T Willis; Lawrence J Mandarino Journal: Biochemistry Date: 2014-06-09 Impact factor: 3.162
Authors: Alex Chao; Xiangmin Zhang; Danjun Ma; Paul Langlais; Moulun Luo; Lawrence J Mandarino; Morgan Zingsheim; Kimberly Pham; James Dillon; Zhengping Yi Journal: J Proteomics Date: 2012-04-06 Impact factor: 4.044
Authors: Sara S Parker; James Krantz; Eun-A Kwak; Natalie K Barker; Chris G Deer; Nam Y Lee; Ghassan Mouneimne; Paul R Langlais Journal: Mol Cell Proteomics Date: 2019-04-24 Impact factor: 5.911